@article {RejA220, author = {Anupam Rej and Matthew Kurien and Paola Tosi and Nick Trott and David Sanders}, title = {PWE-145 The role of a gluten free diet in {\textquoteleft}lifestylers{\textquoteright}? the first double blind randomised study}, volume = {67}, number = {Suppl 1}, pages = {A220--A220}, year = {2018}, doi = {10.1136/gutjnl-2018-BSGAbstracts.439}, publisher = {BMJ Publishing Group}, abstract = {Introduction A gluten free diet (GFD) is essential in the management of coeliac disease, as well as several studies demonstrating its utility as a dietary therapy in patients with irritable bowel syndrome. The aim of this double-blind placebo-controlled study was to assess the role of a GFD in a healthy population who take a GFD as a lifestyle choice ({\textquoteleft}lifestylers{\textquoteright}).Methods Subjects were recruited via an advert, following exclusion criteria including coeliac disease. Following selection, subjects were commenced on a 2 week GFD following evaluation by a dietitian. Participants were then randomised to receive either organic gluten (Group A, Vital Gluten 14 g gluten protein/day) or gluten free flour (Group B) in pre-made bags, over a 2 week period. These were sprinkled on their food twice daily. Gastrointestinal Symptom Rating Scale (GSRS) scores were assessed at baseline (following 2 weeks GFD) and after 2 weeks of randomization. Data was analysed using SPSS version 22.Results 45 subjects were identified with 28 participants recruited into the trial (Group A; n>=14, Group B; n>=14) following exclusion criteria. Median age was 36.5 years (range: 19{\textendash}63) and 21 (75\%) were female. There was no significant difference in baseline demographics between both groups (p>=0.54). Over a 2 week period there was no significant difference in gastrointestinal symptoms or fatigue in either group, as seen in table 1.View this table:Abstract PWE-145 Table 1 Conclusion This study demonstrates that gluten is unlikely to be the culprit agent for gastrointestinal symptoms or fatigue in healthy individuals. A GFD has no evidence base in individuals who do not have coeliac disease or IBS. The public should be discouraged from considering a GFD of their own volition.}, issn = {0017-5749}, URL = {https://gut.bmj.com/content/67/Suppl_1/A220.1}, eprint = {https://gut.bmj.com/content/67/Suppl_1/A220.1.full.pdf}, journal = {Gut} }